Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ancard.2020.09.027 http://scihub22266oqcxt.onion/10.1016/j.ancard.2020.09.027 33081917!7522640!33081917     free     free     free       Ann+Cardiol+Angeiol+(Paris) 2020 ; 69 (6): 370-375 Nephropedia Template TP {{tp|p=33081917|t=2020. COVID-19 et pathologie thromboembolique veineuse |pdf=|usr=}}{{33081917}} gab.com Text COVID-19 et pathologie thromboembolique veineuse JO: Ann Cardiol Angeiol (Paris) http://www.kidney.de/pget.php?&tw=1&pmid=33081917 #FOAvip Coronavirus disease 2019 (COVID-19) is associated with an increased incidence of venous thromboembolism (VTE). Frequently asymptomatic, VTE has a negative impact on patients clinical course. On top of traditional VTE risk factors encountered during COVID-19 such as prolonged bed rest, hypoxemia and intravascular material, main features of patients with severe forms (old age, obesity) explain in part the VTE frequency. In addition, COVID-19 causes an endothelial disease following endotheliitis after the direct invasion of endothelial cells and a prothrombotic state secondary to the strong inflammatory response to infection. Altogether, these mechanisms lead to an extensive immunothrombosis within the pulmonary vasculature. VTE risk stratification to prescribe adequate anticoagulation is an imperious requirement in the COVID-19 treatment. So far, guidelines are mainly based on observational data. Randomized controlled clinical trials are ongoing and will allow to precise the anticoagulant regiment of patients hospitalized for COVID-19. Twit Text FOAVip COVID-19 et pathologie thromboembolique veineuse ????Ann Cardiol Angeiol (Paris) http://www.kidney.de/pget.php?&tw=1&pmid=33081917 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33081917 #FOAvip English Wikipedia <ref>{{Cite pmid|33081917}}</ref> COVID-19 et pathologie thromboembolique veineuse #MMPMID33081917 Trimaille A; Bonnet G Ann Cardiol Angeiol (Paris) 2020[Dec]; 69 (6): 370-375 PMID33081917show ga Coronavirus disease 2019 (COVID-19) is associated with an increased incidence of venous thromboembolism (VTE). Frequently asymptomatic, VTE has a negative impact on patients clinical course. On top of traditional VTE risk factors encountered during COVID-19 such as prolonged bed rest, hypoxemia and intravascular material, main features of patients with severe forms (old age, obesity) explain in part the VTE frequency. In addition, COVID-19 causes an endothelial disease following endotheliitis after the direct invasion of endothelial cells and a prothrombotic state secondary to the strong inflammatory response to infection. Altogether, these mechanisms lead to an extensive immunothrombosis within the pulmonary vasculature. VTE risk stratification to prescribe adequate anticoagulation is an imperious requirement in the COVID-19 treatment. So far, guidelines are mainly based on observational data. Randomized controlled clinical trials are ongoing and will allow to precise the anticoagulant regiment of patients hospitalized for COVID-19. |COVID-19/*complications/physiopathology/therapy[MESH] |Humans[MESH]COVID-19 et pathologie thromboembolique veineuse (epmc).pdf DeepDyve Pubget Overpricing